People · Operator
Named in public records as an officer, director or promoter · active 2017–2023 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Onspira Therapeutics, Inc. | — | Pharmaceuticals | Seed | $1.9M | $73.2M | 2017 |
| Adolore Biotherapeutics, Inc. | — | Biotechnology | Seed | $1.3M | $6.9M | 2022 |
Roy Levitt at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Roy Levitt on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Paul Barone | 2 | 2 |
| Stephen Tullman | 1 | 7 |
| Mark Rogers | 1 | 6 |
| Douglas Gessl | 1 | 4 |
| Roelof Rongen | 1 | 3 |
| Lou Altieri | 1 | 1 |
| Brian Lortie | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.